Gilead Sciences Q3 EPS Estimate Raised by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Zacks Research raised their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Tuesday, December 30th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $2.34 for the quarter, up from their previous estimate of $2.32. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q1 2027 earnings at $1.98 EPS, Q2 2027 earnings at $2.15 EPS, Q3 2027 earnings at $2.58 EPS and FY2027 earnings at $9.11 EPS.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS.

GILD has been the subject of a number of other reports. TD Cowen lifted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Morgan Stanley raised their price objective on Gilead Sciences from $147.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the company an “outperform” rating in a report on Monday. The Goldman Sachs Group increased their target price on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Finally, UBS Group upgraded Gilead Sciences to a “hold” rating in a research report on Thursday, December 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $131.68.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $122.74 on Thursday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $152.28 billion, a price-to-earnings ratio of 19.03, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33. Gilead Sciences has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a 50-day simple moving average of $123.04 and a two-hundred day simple moving average of $116.97.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the third quarter valued at about $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the second quarter worth about $27,000. Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $30,000. Finally, Putney Financial Group LLC raised its holdings in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the insider owned 106,221 shares of the company’s stock, valued at approximately $12,958,962. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 136,257 shares of company stock valued at $16,855,192 over the last ninety days. 0.27% of the stock is owned by insiders.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.